As a novice investor, I recently bought shares of $Eli Lilly(LLY)$ at what I believe was the bottom, as part of my diversification strategy to mitigate tariff impact. I chose Eli Lilly for its strong fundamentals, including a robust pipeline of innovative drugs, such as its popular diabetes and obesity treatments. By investing in Eli Lilly, I aim to reduce my reliance on other sectors and benefit from the company's relatively lower exposure to tariffs, as pharmaceuticals are essential products. I plan to monitor tariff developments, track Eli Lilly's performance, and rebalance my portfolio as needed to maintain an optimal asset allocation and minimize risk.